Actively Recruiting
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Led by Celyad Oncology SA · Updated on 2020-11-20
49
Participants Needed
4
Research Sites
898 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy
CONDITIONS
Official Title
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed metastatic adenocarcinoma of the colon or rectum
- Confirmed metastatic unresectable adenocarcinoma of the colon or rectum
- Recurrent or progressing disease after at least one systemic therapy for metastatic disease
- Measurable disease by RECIST version 1.1 criteria
- For FOLFOX group: Neurotoxicity from prior chemotherapy grade 1 or less by CTCAE
- For FOLFIRI group: Progressive disease during FOLFIRI treatment within 3 months before study registration; no anticancer therapy except radiotherapy discontinued at least 7 days before registration
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate bone marrow, liver, kidney, lung, and heart function
You will not qualify if you...
- Confirmed or history of tumor involvement in the central nervous system
- Use of any non-cancer investigational agent within 3 weeks before first CYAD-101 dose
- Use of filgrastim (G-CSF) or similar growth factors within 7 days before first CYAD-101 dose
- Prior allogeneic stem cell transplantation, CAR T-cell therapy, or other genetically modified T-cell therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Moffit Cancer Center
Tampa, Florida, United States, 33612
Not Yet Recruiting
2
Institut Jules Bordet
Brussels, Belgium, 1000
Actively Recruiting
3
UZ Antwerpen
Edegem, Belgium, 2650
Actively Recruiting
4
UZ Leuven
Leuven, Belgium, 3000
Actively Recruiting
Research Team
C
Celyad Oncology Medical Monitor, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here